Schrodinger Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Schrodinger Inc 公司

Schrodinger, Inc. 运营一个基于物理的计算平台，该平台能够发现用于药物开发和材料应用的分子。该软件平台被世界各地的生物制药和工业公司、学术机构和政府实验室使用。该公司通过两个部门运营：软件和药物发现。软件部门专注于销售其软件，以改变整个生命科学行业以及材料科学行业的药物发现。药物发现部门专注于通过内部和合作建立多样化的临床前和临床项目组合，这些项目已进入发现和开发的各个阶段。该公司的药物发现项目包括 SGR-1505（MALT1 抑制剂）、SGR-2921（CDC7 抑制剂）、SGR-3515（WEE1 抑制剂）。其软件被全球 1,760 多家学术机构的研究人员使用。

公司简介

公司代码SDGR

公司名称Schrodinger Inc

上市日期Feb 06, 2020

CEODr. Ramy Farid, Ph.D.

员工数量891

证券类型Ordinary Share

年结日Feb 06

公司地址1540 Broadway

城市NEW YORK

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编10036

电话15032991150

网址https://www.schrodinger.com

公司代码SDGR

上市日期Feb 06, 2020

CEODr. Ramy Farid, Ph.D.

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Richard A. Friesner, Ph.D.

Director

1.24M

+0.49%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

36.99K

-30.96%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

25.97K

+92.81%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

23.64K

+112.26%

Mr. Arun Oberoi

Independent Director

12.25K

+95.95%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

12.25K

+95.95%

Michael M. Lynton ,

Independent Chairman of the Board

12.25K

+95.95%

Ms. Bridget Anne Van Kralingen

Independent Director

11.50K

+14.99%

Mannix Aklian

Executive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing

--

Mr. Gary Ginsberg, J.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Richard A. Friesner, Ph.D.

Director

1.24M

+0.49%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

36.99K

-30.96%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

25.97K

+92.81%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

23.64K

+112.26%

Mr. Arun Oberoi

Independent Director

12.25K

+95.95%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

12.25K

+95.95%

收入明细

单位: USD更新时间: 7月6日周日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

On-premise software

25.42M

42.69%

Hosted software

10.87M

18.26%

Drug discovery services

10.24M

17.19%

Software maintenance

6.80M

11.41%

Contribution

3.84M

6.45%

Other

2.38M

4.00%

地区USD

名称

营收

占比

United States

29.66M

49.81%

EMEA

23.08M

38.76%

APAC

6.07M

10.20%

Rest of World

731.00K

1.23%

业务

地区

业务USD

名称

营收

占比

On-premise software

25.42M

42.69%

Hosted software

10.87M

18.26%

Drug discovery services

10.24M

17.19%

Software maintenance

6.80M

11.41%

Contribution

3.84M

6.45%

Other

2.38M

4.00%

股东统计

更新时间: 5月23日周五

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

12.07%

Bill & Melinda Gates Foundation Trust

10.87%

The Vanguard Group, Inc.

10.17%

Rubric Capital Management LP

7.48%

Nikko Asset Management Co., Ltd.

5.68%

Other

53.73%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

12.07%

Bill & Melinda Gates Foundation Trust

10.87%

The Vanguard Group, Inc.

10.17%

Rubric Capital Management LP

7.48%

Nikko Asset Management Co., Ltd.

5.68%

Other

53.73%

股东类型

持股股东

占比

Investment Advisor

48.38%

Investment Advisor/Hedge Fund

25.00%

Hedge Fund

13.63%

Endowment Fund

10.87%

Individual Investor

2.65%

Research Firm

2.22%

Pension Fund

0.80%

Bank and Trust

0.49%

Venture Capital

0.13%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

570

67.20M

104.65%

-5.08M

2025Q1

593

67.21M

104.69%

-5.43M

2024Q4

576

64.44M

100.89%

-9.04M

2024Q3

581

67.44M

105.91%

-6.15M

2024Q2

573

64.76M

101.80%

-8.12M

2024Q1

574

63.48M

100.05%

-5.40M

2023Q4

584

62.06M

98.56%

-7.64M

2023Q3

586

63.62M

101.35%

-15.42M

2023Q2

584

64.04M

102.20%

-7.30M

2023Q1

543

57.09M

91.59%

-11.19M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

7.75M

12.07%

-354.21K

-4.37%

Mar 31, 2025

Bill & Melinda Gates Foundation Trust

6.98M

10.87%

--

Mar 31, 2025

The Vanguard Group, Inc.

6.53M

10.17%

-72.09K

-1.09%

Mar 31, 2025

Rubric Capital Management LP

4.80M

7.48%

-200.00K

-4.00%

Mar 31, 2025

Nikko Asset Management Co., Ltd.

3.46M

5.39%

-48.10K

-1.37%

Mar 31, 2025

UBS Asset Management (Switzerland)

2.47M

3.85%

+919.38K

+59.31%

Mar 31, 2025

Stephens Investment Management Group, LLC

1.97M

3.07%

+362.29K

+22.53%

Mar 31, 2025

State Street Global Advisors (US)

2.21M

3.44%

-104.66K

-4.52%

Mar 31, 2025

MFS Investment Management

2.09M

3.26%

-186.23K

-8.17%

Mar 31, 2025

ARK Investment Management LLC

2.29M

3.57%

+85.76K

+3.88%

Mar 31, 2025

持股ETF

更新时间: 8月2日周六

机构名称

占比

ARK Genomic Revolution ETF

3.78%

TrueShares Technology, AI & Deep Learning ETF

2.24%

Global X HealthTech ETF

1.25%

SPDR FactSet Innovative Technology ETF

0.97%

WisdomTree BioRevolution Fund

0.84%

Franklin Exponential Data ETF

0.81%

Invesco S&P SmallCap Health Care ETF

0.8%

Franklin Genomic Advancements ETF

0.63%

First Trust Multi-Manager Small Cap Opportunities ETF

0.46%

First Trust Nasdaq Lux Digi Health Solutions ETF

0.44%

ARK Genomic Revolution ETF

占比3.78%

TrueShares Technology, AI & Deep Learning ETF

占比2.24%

Global X HealthTech ETF

占比1.25%

SPDR FactSet Innovative Technology ETF

占比0.97%

WisdomTree BioRevolution Fund

占比0.84%

Franklin Exponential Data ETF

占比0.81%

Invesco S&P SmallCap Health Care ETF

占比0.8%

Franklin Genomic Advancements ETF

占比0.63%

First Trust Multi-Manager Small Cap Opportunities ETF

占比0.46%

First Trust Nasdaq Lux Digi Health Solutions ETF

占比0.44%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Schrodinger Inc

19.775USD

Schrodinger Inc

19.775

概览

公司

财务